Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at Holmes Murphy share what to consider when evaluating GLP-1s for your ...